Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Endocrinology|February 27, 2010
Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cellsTeresa Coll, David Alvarez-Guardia, Emma Barroso, et al.
Endocrinology|December 22, 2009
Cyclooxygenase 2 inhibition exacerbates palmitate-induced inflammation and insulin resistance in skeletal muscle cellsTeresa Coll, Xavier Palomer, Francisco Blanco-Vaca, et al.
The Journal of Biological Chemistry|February 19, 2008
Oleate reverses palmitate-induced insulin resistance and inflammation in skeletal muscle cellsTeresa Coll, Elena Eyre, Ricardo Rodríguez-Calvo, et al.
Cell Communication and Signaling : CCS|December 19, 2024
PPARβ/δ upregulates the insulin receptor β subunit in skeletal muscle by reducing lysosomal activity and EphB4 levelsJue-Rui Wang, Javier Jurado-Aguilar, Emma Barroso, et al.
Cell Reports|August 11, 2021
GDF15 mediates the metabolic effects of PPARβ/δ by activating AMPKDavid Aguilar-Recarte, Emma Barroso, Anna Gumà, et al.
Clinical Chemistry|May 25, 2004
Evaluation of two nonisotopic immunoassays for determination of glutamic acid decarboxylase and tyrosine phosphatase autoantibodies in serumXavier Palomer, Dídac Mauricio, José Rodríguez-Espinosa, et al.
Hepatology (Baltimore, Md.)|December 5, 2008
Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase ARicardo Rodríguez-Calvo, Emma Barroso, Lucía Serrano, et al.
International Journal of Molecular Sciences|March 21, 2018
PPARβ/δ: A Key Therapeutic Target in Metabolic DisordersXavier Palomer, Emma Barroso, Javier Pizarro-Delgado, et al.
International Journal of Cardiology|April 29, 2014
PPARβ/δ attenuates palmitate-induced endoplasmic reticulum stress and induces autophagic markers in human cardiac cellsXavier Palomer, Eva Capdevila-Busquets, Gaia Botteri, et al.
British Journal of Pharmacology|March 31, 2019
Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21Mohammad Zarei, Eugènia Pujol, Tania Quesada-López, et al.
Pageof 9